200 related articles for article (PubMed ID: 26587321)
1. GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells
Pedroza-Gonzalez A; Zhou G; Singh SP; Boor PP; Pan Q; Grunhagen D; de Jonge J; Tran TK; Verhoef C; IJzermans JN; Janssen H; Biermann K; Kwekkeboom J; Sprengers D
Oncoimmunology; 2015 Dec; 4(12):e1051297. PubMed ID: 26587321
[TBL] [Abstract][Full Text] [Related]
2. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer.
Pedroza-Gonzalez A; Verhoef C; Ijzermans JN; Peppelenbosch MP; Kwekkeboom J; Verheij J; Janssen HL; Sprengers D
Hepatology; 2013 Jan; 57(1):183-94. PubMed ID: 22911397
[TBL] [Abstract][Full Text] [Related]
3. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
4. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
[TBL] [Abstract][Full Text] [Related]
5. GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells.
Rakké YS; Campos Carrascosa L; van Beek AA; de Ruiter V; van Gemerden RS; Doukas M; Doornebosch PG; Vermaas M; Ter Borg S; van der Harst E; Coene PPLO; Kliffen M; Grünhagen DJ; Verhoef C; IJzermans JNM; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2023; 15(1):77-97. PubMed ID: 36155259
[TBL] [Abstract][Full Text] [Related]
6. Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.
Kim YH; Shin SM; Choi BK; Oh HS; Kim CH; Lee SJ; Kim KH; Lee DG; Park SH; Kwon BS
J Immunol; 2015 Nov; 195(10):4721-9. PubMed ID: 26423152
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
8. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic characterization of ex vivo CD4+CD25highCD127low immune regulatory T cells in allergic asthma: pathogenesis relevance of their FoxP3, GITR, CTLA-4 and FAS expressions.
Pietruczuk M; Eusebio M; Kraszula L; Kupczyk M; Kuna P
J Biol Regul Homeost Agents; 2012; 26(4):627-39. PubMed ID: 23241113
[TBL] [Abstract][Full Text] [Related]
10. The glucocorticoid-induced TNF receptor-related protein (GITR)-GITR ligand pathway acts as a mediator of cutaneous dendritic cell migration and promotes T cell-mediated acquired immunity.
Kamimura Y; Iwai H; Piao J; Hashiguchi M; Azuma M
J Immunol; 2009 Mar; 182(5):2708-16. PubMed ID: 19234165
[TBL] [Abstract][Full Text] [Related]
11. GITR ligand-costimulation activates effector and regulatory functions of CD4+ T cells.
Igarashi H; Cao Y; Iwai H; Piao J; Kamimura Y; Hashiguchi M; Amagasa T; Azuma M
Biochem Biophys Res Commun; 2008 May; 369(4):1134-8. PubMed ID: 18346459
[TBL] [Abstract][Full Text] [Related]
12. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
13. [Specific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patients].
Zhang HH; Fei R; Xie XW; Wang L; Luo H; Wang XY; Wei L; Chen HS
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 41(3):313-8. PubMed ID: 19727215
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Regulatory T Cell-Related Markers (FOXP3, CTLA-4 and GITR) by Peripheral Blood Mononuclear Cells from Patients with Breast Cancer.
Khalife E; Khodadadi A; Talaeizadeh A; Rahimian L; Nemati M; Jafarzadeh A
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3019-3025. PubMed ID: 30484986
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid-Induced TNF Receptor Family-Related Protein Ligand is Requisite for Optimal Functioning of Regulatory CD4(+) T Cells.
Liao G; O'Keeffe MS; Wang G; van Driel B; de Waal Malefyt R; Reinecker HC; Herzog RW; Terhorst C
Front Immunol; 2014; 5():35. PubMed ID: 24550919
[TBL] [Abstract][Full Text] [Related]
16. In vivo fluctuation of Tax, Foxp3, CTLA-4, and GITR mRNA expression in CD4(+)CD25(+) T cells of patients with human T-lymphotropic virus type 1-associated myelopathy.
Ramirez E; Cartier L; Rodriguez L; Alberti C; Valenzuela MA
Braz J Med Biol Res; 2010 Nov; 43(11):1109-15. PubMed ID: 20945034
[TBL] [Abstract][Full Text] [Related]
17. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
[TBL] [Abstract][Full Text] [Related]
18. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M
J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216
[TBL] [Abstract][Full Text] [Related]
19. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules.
Nishioka T; Nishida E; Iida R; Morita A; Shimizu J
Immunol Lett; 2008 Dec; 121(2):97-104. PubMed ID: 18930767
[TBL] [Abstract][Full Text] [Related]
20. Targeting GITR in cancer immunotherapy - there is no perfect knowledge.
Davar D; Zappasodi R
Oncotarget; 2023 Jun; 14():614-621. PubMed ID: 37335294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]